Brilinta Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

60 mg: Each film-coated tablet contains 60 mg ticagrelor.
90 mg: Each film-coated tablet contains 90 mg ticagrelor.
Brilinta contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially 'sodium-free'.
Excipients/Inactive Ingredients: 60 mg: Tablet core: Mannitol (E421), Dibasic calcium phosphate dihydrate, Magnesium stearate (E470b), Sodium starch glycolate type A, Hydroxypropylcellulose (E463).
Tablet coating: Titanium dioxide (E171), Ferric oxide black (E172), Ferric oxide red (E172), Polyethylene glycol 400, Hypromellose (E464).
90 mg: Core: Mannitol (E421), Dibasic calcium phosphate, Magnesium stearate (E470b), Sodium starch glycolate, Hydroxypropyl-cellulose (E463).
Coating: Talc, Titanium dioxide (E171), Ferric oxide yellow (E172), Polyethylene-glycol 400, Hypromellose (E464).

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma